Table 1 Patient, tumor and treatment characteristics in the total population and according to the panel defined at randomization
Characteristics | All patients (n = 339) | Patients with molecular profile achieved with F1CDX (n = 171) | Patients with molecular profile achieved with CTL (n = 168) | |||
|---|---|---|---|---|---|---|
Sex | ||||||
Male | 153 (45.1%) | 74 (43.3%) | 79 (47.0%) | |||
Female | 186 (54.9%) | 97 (56.7%) | 89 (53.0%) | |||
Median age at inclusion (years) | 57.0 (19.0–85.0) | 56.0 (20.0–81.0) | 57.5 (19.0–85.0) | |||
Metastatic status | ||||||
M0 | 117 (34.5%) | 53 (31.0%) | 64 (38.1%) | |||
M1 | 222 (65.5%) | 118 (69.0%) | 104 (61.9%) | |||
Tumor localization or type | ||||||
Breast | 30 (8.8%) | 20 (11.7%) | 10 (6.0%) | |||
Unknown primary site | 6 (1.8%) | 3 (1.8%) | 3 (1.8%) | |||
Genitourinary | 28 (8.3%) | 11 (6.4%) | 17 (10.1%) | |||
Glioma | 81 (23.9%) | 40 (23.4%) | 41 (24.4%) | |||
Gynecological | 44 (13.0%) | 26 (15.2%) | 18 (10.7%) | |||
Head and neck | 10 (2.9%) | 4 (2.3%) | 6 (3.6%) | |||
Liver and cholangiocarcinoma (BTC, HCC) | 16 (4.7%) | 6 (3.5%) | 10 (6.0%) | |||
Colon | 9 (2.7%) | 4 (2.3%) | 5 (3.0%) | |||
Lung | 13 (3.8%) | 5 (2.9%) | 8 (4.8%) | |||
Melanoma | 1 (0.3%) | 0 (0%) | 1 (0.6%) | |||
Pancreatic | 14 (4.1%) | 7 (4.1%) | 6 (3.6%) | |||
Renal | 7 (2.1%) | 5 (2.9%) | 2 (1.2%) | |||
Sarcoma | 41 (12.1%) | 19 (11.1%) | 22 (13.1%) | |||
Gastroesophageal | 17 (5.0%) | 9 (5.3%) | 8 (4.8%) | |||
Mesothelioma | 13 (3.8%) | 5 (2.9%) | 8 (4.8%) | |||
Pancreatic | 7 (4.2%) | 0 (0%) | 1 (0.6%) | |||
Thyroid | 4 (1.2%) | 2 (1.2%) | 2 (1.2%) | |||
Thymoma | 5 (1.5%) | 5 (2.9%) | 0 (0%) | |||
Treatment line at inclusion | ||||||
Not specified | 37 (10.9%) | 13 (7.6%) | 24 (14.3%) | |||
First line | 193 (56.9%) | 104 (60.8%) | 89 (53.0%) | |||
Second line | 107 (31.6%) | 54 (31.6%) | 53 (31.5%) | |||
Third line | 2 (0.6%) | 0 (0%) | 2 (1.2%) | |||
Median time from randomization to MTB#1 (months) | 7.62 (0.8–48.1) | 8.08 (0.9–48.1) | 6.87 (0.8–39.1) | |||
